PBYIPuma Biotechnology, Inc.Signing up patients
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer ( SCLC )
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 50 (planned)
- Started
- Sep 17, 2026
- Main results expected
- Mar 31, 2028
- Fully finished
- Sep 30, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants with Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events)
Measured over: From date of first dose through last dose plus 28 days, assessed up to 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07465757 · record last updated 2026-11-02 · checked 2026-11-09 15:36 UTC